JAMA & Archives
SEARCH
GO TO ADVANCED SEARCH
-
HOME  SUBSCRIPTIONS  E-MAIL ALERTS  TOPIC COLLECTIONS  CME  PHYSICIAN JOBS  CONTACT US  HELP

Adverse Effects

Contributing journals to this collection:
JAMA & Archives Journals

Citations 131-140 of 1622 total displayed.

Past content

Arch Intern Med
Research Letters
Patient- and Physician-Oriented Web Sites and Drug Surveillance: Bisphosphonates and Severe Bone, Joint, and Muscle Pain
Harold J. DeMonaco
Arch Intern Med 2009; 169: 1164-1166. [Extract] [Full text] [PDF]  

JAMA
Medical News & Perspectives
Children’s Exposure to Testosterone Gel Spurs FDA to Order Boxed Label Warning
Rebecca Voelker
JAMA 2009; 301: 2428. [Extract] [Full text] [PDF]  

JAMA
Letters
Comparing Dexmedetomidine With Midazolam for Sedation of Patients in the ICU
Mohamed Y. Rady; Bhavesh M. Patel; Joel S. Larson
JAMA 2009; 301: 2439-a-2440-a. [Extract] [Full text] [PDF]  

JAMA
Letters
Comparing Dexmedetomidine With Midazolam for Sedation of Patients in the ICU
Jack DePriest; Luis Gonzalez III
JAMA 2009; 301: 2439. [Extract] [Full text] [PDF]  

JAMA
Letters
Comparing Dexmedetomidine With Midazolam for Sedation of Patients in the ICU
Amit Gupta; David Lee; Mark Su
JAMA 2009; 301: 2440-a-2441-a. [Extract] [Full text] [PDF]  

JAMA
Letters
Comparing Dexmedetomidine With Midazolam for Sedation of Patients in the ICU
Christopher Paciullo
JAMA 2009; 301: 2440. [Extract] [Full text] [PDF]  

JAMA
Letters
Comparing Dexmedetomidine With Midazolam for Sedation of Patients in the ICU—Reply
Richard R. Riker; Yahya Shehabi; Marcelo G. Rocha
JAMA 2009; 301: 2441-2442. [Extract] [Full text] [PDF]  

JAMA
JAMA Classics
Postmenopausal Hormone Treatment
Stephen Hulley; Deborah Grady
JAMA 2009; 301: 2493-2495. [Extract] [Full text] [PDF] [ Original Article ]  

JAMA
Medical News & Perspectives
Patients Warned About Risks of Drugs Used for Analgesia, Fevers, Addiction
Bridget M. Kuehn
JAMA 2009; 301: 2315-2316. [Extract] [Full text] [PDF]  

JAMA
Medical News & Perspectives
FDA Requires Black Box Warnings on Labeling for Botulinum Toxin Products
Bridget M. Kuehn
JAMA 2009; 301: 2316. [Extract] [Full text] [PDF]  

[First page]   [Previous page]   [Next page]
Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163

 Collections
 •Topic Collections Home
 •Related collections:
  •Drug Therapy
  •Adherence
  •Adverse Effects
  •Medication Error
  •Pediatric Dosing
  •Drug Therapy, Other
Advertisement




HOME | SUBSCRIPTIONS | E-MAIL ALERTS | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.